In studies examining CD133 expression in primary CRC tissues, using immunohistochemistry to assess its association with OS, Kojima et al. analyzed 160 patients with stage I–IV CRC and reported that CD133 expression was associated with poor prognosis [51]. Here, PROM1 is linked to colorectal carcinoma.